Aurinia Pharmaceuticals (AUPH) vs. Its Competitors Critical Review

Aurinia Pharmaceuticals (NASDAQ:AUPH) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Aurinia Pharmaceuticals to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Insider and Institutional Ownership

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Aurinia Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	97.68%	22.99%	17.99%
Aurinia Pharmaceuticals Competitors	-12,357.18%	-197.96%	-30.56%

Analyst Recommendations

This is a summary of recent recommendations for Aurinia Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	2	1	2.67
Aurinia Pharmaceuticals Competitors	9838	15122	45436	1587	2.54

Aurinia Pharmaceuticals presently has a consensus target price of $17.33, indicating a potential upside of 5.31%. As a group, “Biotechnology” companies have a potential upside of 102.73%. Given Aurinia Pharmaceuticals’ competitors higher possible upside, analysts clearly believe Aurinia Pharmaceuticals has less favorable growth aspects than its competitors.

Volatility and Risk

Aurinia Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals’ competitors have a beta of 1.15, meaning that their average share price is 15% more volatile than the S&P 500.

Earnings and Valuation

This table compares Aurinia Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aurinia Pharmaceuticals	$321.74 million	$287.20 million	7.19
Aurinia Pharmaceuticals Competitors	$728.25 million	$12.25 million	-15.19

Aurinia Pharmaceuticals’ competitors have higher revenue, but lower earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Aurinia Pharmaceuticals beats its competitors on 8 of the 13 factors compared.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.